Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have been given a consensus rating of “Buy” by the seven ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...

The company is also carrying out a pair of phase 3 trials in cutaneous melanoma – PRISM-MEL-301 and TEBE-AM – and is due to start a third in adjuvant uveal melanoma (ATOM) before year-end.

Stephens Inc. AR reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 4.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,439 shares ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank ...

The pharmaceutical industry is highly regulated and maintains strict standards of precision. Embracing automation and the advanced digital tools conceived through the principles of Pharma 4.0 aim to ...

Ideaya Biosciences ( ($IDYA) ) has released its Q4 earnings. Here is a breakdown of the information Ideaya Biosciences presented to its investors.

Like most human traits, blue eyes are determined by genes, and no two people have exactly the same hue. It works a lot like ...